Editorial: Management of the congenitally abnormal right ventricular outflow tract—what is the right approach?  by Hanley, Frank L.
O ne measure of progress in medicine is the introduc-tion of new and superior treatment options, which
naturally replace older forms of therapy. Sometimes,
newly introduced treatment options compete against,
rather than replace, older more established treatments.
This is especially true when different forms of therapy
for the same disease have their origins in different dis-
ciplines. In line with recent trends in the management
of congenital heart disease, percutaneous catheter-
based procedures have recently been introduced for
managing the obstructed right ventricular outflow tract
(RVOT). Under certain circumstances, these procedures
may be considered as an alternative to “open heart”
reconstructive operations. Such innovations are a wel-
come addition; however, their efficacy should be care-
fully evaluated. There are many benefits to a medical
environment in which the development and introduction
of new procedures is given high priority. Most obvious-
ly, when a new form of therapy is shown to be superior,
the entire field is advanced. Substantial benefits can
also be gained, however, even when newly introduced
treatment options are shown to be no better than, or
possibly even inferior to, more established forms of
therapy. Under these circumstances we are forced to
reevaluate our more established procedures and man-
agement philosophies in the light of the newly intro-
duced competition.
With respect to both surgical and interventional pro-
cedures directed at the congenitally obstructed RVOT,
therapy is often initiated in response to detected hemo-
dynamic abnormalities that reach a predetermined
threshold. The short-term goal of these procedures is to
improve the hemodynamic status of the patient.
Furthermore, the success of a given procedure is usual-
ly judged by the degree to which the abnormal hemo-
dynamics are improved. An RVOT valved conduit oper-
ation is considered successful if the patient’s
hemodynamics are changed from a preoperative RVOT
gradient of 70 mm Hg with moderate pulmonary insuf-
ficiency to a postoperative status of no gradient with
trivial pulmonary insufficiency. These short-term hemo-
dynamic measures, however, are not the true yardstick
of success. Successful elimination of deranged hemo-
dynamics is important, not in and of itself, but only for
what it implies with respect to the long-term health of
the right ventricular myocardium. The real reason to
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intervene is to improve life expectancy of the right side
of the heart. To be sure, normalization of the deranged
hemodynamics will go a long way to accomplish this
long-term goal. Numerous studies in both human
beings and animal models suggest that even moderate
hemodynamic derangements (both pressure and vol-
ume loads), if chronic, can cause irreversible changes
in the myocardium, including increased collagen con-
tent in the interstitium, ischemic myocyte loss, and
dysfunction of the atrioventricular valve.1-5 Such
changes in the ventricular myocardium are not re-
versible, and the long-term viability of the ventricle
will inevitably be affected negatively if they are
allowed to occur.
When a given intervention only partially normalizes
the hemodynamic derangement or trades one hemody-
namic derangement for another, it is less clear that the
long-term outlook for the ventricular myocardium will
be improved. Recently, Ovaert and colleagues6 report-
ed on the use of percutaneously introduced intravascu-
lar stents to relieve RVOT gradients in existing surgi-
cally placed conduits in patients with lesions such as
tetralogy of Fallot, tetralogy of Fallot with pulmonary
atresia, truncus arteriosus, transposition of the great
vessels, and double-outlet right ventricle. Their patients
had significant conduit stenosis, such that they would
otherwise be considered candidates for surgical conduit
revision. (In the authors’ institution, the traditional cri-
terion for conduit revision is a right ventricular pressure
that equals two thirds the left ventricular pressure.) In
this patient population, stent enlargement of the stenot-
ic RVOT conduit at the level of the valve was per-
formed, rather than subjecting the patient to an opera-
tion. A review of the stent procedure in 42 patients
shows that the RVOT obstruction was modestly
relieved, with right ventricular pressure dropping from
an average of 71 mm Hg to 48 mm Hg. The authors stat-
ed that the procedure lowered the right ventricular/left
ventricular pressure ratio below their criterion for per-
forming conduit replacement. As a result, surgical con-
duit revision or replacement was delayed substantially,
with approximately 50% of the patients remaining free
from surgical conduit revision at 3 years.
It is clear that stenting an obstructed conduit can
reduce an RVOT gradient significantly and, in so doing,
can delay the need for surgical conduit revision if the
criterion for conduit revision is based solely on a spe-
cific gradient. What is less clear is whether stenting in
this setting actually improves the long-term outlook for
the right ventricular myocardium. According to Ovaert’s
data, residual gradients were present immediately after
the stent procedure, with a reduction in right ventricular
systolic pressure of only 23 mm Hg. Furthermore, there
are no data on whether the stent procedures resulted in
increased conduit insufficiency. In almost all cases, the
stents were placed at the level of the valve of the con-
duit. The cross-sectional area at the level of the stent
was increased 133%. Given these observations, it seems
reasonable to be concerned that stenting a valved con-
duit is likely to result in severe conduit insufficiency.
One is left to ask how best to ensure the long-term
health of a right ventricle that starts out with a 70–mm
Hg systolic pressure and mild to moderate pulmonary
insufficiency. Is it better to do a stent procedure that
reduces the right ventricular systolic pressure to approx-
imately 50 mm Hg, but in the process increases the pul-
monary insufficiency to a severe level, or to do a surgi-
cal conduit replacement that eliminates the gradient and
eliminates insufficiency? 
Is pulmonary insufficiency an important issue? It is
clear from the long-term follow-up of patients who
received generous transannular patches for the treat-
ment of tetralogy of Fallot and have severe pulmonary
insufficiency and absent outflow gradients that severe
pulmonary insufficiency can be very detrimental to the
health of the right ventricular myocardium. On the
other hand, the answer to the question of whether a
stent or a conduit replacement is most appropriate in
the example given above is not so clear. If the optimal
early postoperative hemodynamics associated with a
conduit replacement were sustainable, there would be
little argument that conduit replacement would be con-
sidered the superior form of therapy. Unfortunately, all
currently available conduits physically degenerate, and
along with this process hemodynamics degenerate as
well.
The stent versus surgery debate currently does not
have a clear winner. However, the debate does under-
score a more important dilemma. Given the available
spectrum of limited therapeutic options for managing
the congenitally abnormal RVOT, how hard should we
work at maintaining ideal, or close to ideal, hemody-
namics? All of the therapeutic options come at a price.
Management strategies that accept significantly abnor-
mal hemodynamics for long periods clearly will limit
the long-term viability of the right ventricular
myocardium. The advantage of this management
scheme is that interventions (surgical or transcatheter)
are kept to a minimum. Management strategies that use
catheter-based percutaneous interventions improve cer-
tain hemodynamic variables modestly (outflow gradi-
ents) but certainly do not eliminate the gradient. Fur-
thermore, other hemodynamic variables (pulmonary
insufficiency) are likely to be made worse. The long-
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term implications of this strategy for the right ventric-
ular myocardium are not clear. The clear attraction of
this strategy is the promise of delaying surgical inter-
vention. The management strategy of surgical conduit
replacement holds the best chance of normalizing
RVOT hemodynamics. Unfortunately, the optimal
hemodynamic performance of conduits is distressingly
transient. The tradeoff for maintaining ideal, or close to
ideal, RVOT hemodynamics, then, is frequent surgical
procedures. How tightly should one control RVOT
hemodynamics in this setting? Although the answer to
this question is not known with certainty, logic would
dictate that the answer is quite similar to that given to
the patient with insulin-dependent diabetes who asks
how tightly should one control serum glucose. The
answer to the diabetic patient is that glucose should be
controlled as tightly as possible while still maintaining
an acceptable quality of life. Similarly, RVOT hemody-
namics should be kept as close to normal as possible
while still allowing the patient an acceptable quality of
life. The difference between the two examples, of
course, is that compulsive timing of meals, counting
calories, and monitoring insulin use is generally
thought to be more acceptable than submitting oneself
to conduit replacements on a regular basis.
There is clearly no single correct solution to the
dilemma of how frequently a patient should undergo
conduit replacement or any other procedure for RVOT
disease. Numerous individual physiologic considera-
tions, as well as the patient’s own philosophy with
respect to quality of life and risk, enter into the decision
at the individual level. Stenting an obstructed conduit
to delay a more invasive surgical procedure certainly
has a place among the therapeutic options that can be
presented to individual patients. It is relatively com-
pelling to suggest a “new” procedure that is less inva-
sive and that postpones surgery for 3 years, on average,
when the alternative option is that the patient undergo
a surgical procedure now. Many patients are sure to
find the stent option attractive, especially if concerns
about the long-term viability of the right ventricular
myocardium are not discussed. On the other hand,
patients should also be made aware that if their priori-
ty is to live as long as possible, or to avoid heart trans-
plantation as long as possible, frequent conduit
replacement with tight control of RVOT hemodynam-
ics is probably the strategy of choice.
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